PMID- 19471888
OWN - NLM
STAT- MEDLINE
DCOM- 20090629
LR  - 20180924
IS  - 0253-6269 (Print)
IS  - 0253-6269 (Linking)
VI  - 32
IP  - 5
DP  - 2009 May
TI  - Maintenance of the viral episome is essential for the cell survival of an 
      Epstein-Barr virus positive gastric carcinoma cell line.
PG  - 729-36
LID - 10.1007/s12272-009-1512-7 [doi]
AB  - While Epstein Barr virus (EBV) is associated with about 10% of gastric carcinomas 
      worldwide, the role of the virus in the tumorigenesis of EBV-associated gastric 
      carcinoma (EBVaGC) is unclear. Previously, we reported that a gastric cancer cell 
      line, SNU-719, that is naturally infected with EBV closely resembles EBVaGC. 
      Here, we attempted to eliminate the EBV genome from SNU-719 cells to ascertain 
      the influence of EBV in EBVaGC. Southern blotting and fluorescence in situ 
      hybridization (FISH) showed that EBV genomes were maintained as episomes in 
      SNU-719 cells. To remove EBV episomes, SNU-719 cells were first cultured in a 
      hydroxyurea (HU)-containing medium for up to 6 months. Real-time polymerase chain 
      reaction and FISH results revealed no evidence of HU-mediated EBV genome 
      reduction, although cell growth was reduced by acute HU treatment in dose- and 
      time-dependent manners. Two small interfering RNAs against Epstein Barr nuclear 
      antigen 1 (EBNA1) abrogated over 90% of the ectopic EBNA1 expression in HeLa 
      cells, but only 40% of endogenous EBNA1 expression in SNU-719 cells. Together, 
      our data suggest that maintenance of latent EBV infection is essential for the 
      viability of EBVaGC cells, avoiding elimination of EBV episomes from the cells.
FAU - Oh, Sang Taek
AU  - Oh ST
AD  - Department of Biomedical Sciences, Catholic University of Korea, Seoul, 137-701, 
      Korea.
FAU - Kim, Myungshin
AU  - Kim M
FAU - Lee, Suk Kyeong
AU  - Lee SK
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090527
PL  - Korea (South)
TA  - Arch Pharm Res
JT  - Archives of pharmacal research
JID - 8000036
RN  - 0 (Epstein-Barr Virus Nuclear Antigens)
RN  - 0 (Nucleic Acid Synthesis Inhibitors)
RN  - 0 (RNA, Small Interfering)
RN  - O5GA75RST7 (EBV-encoded nuclear antigen 1)
RN  - X6Q56QN5QC (Hydroxyurea)
SB  - IM
CIN - Arch Pharm Res. 2009 May;32(5):637-8. PMID: 19471875
MH  - Blotting, Southern
MH  - Carcinoma/pathology/*virology
MH  - Cell Proliferation
MH  - Cell Survival
MH  - Cell Transformation, Viral/*genetics
MH  - Dose-Response Relationship, Drug
MH  - Epstein-Barr Virus Nuclear Antigens/*genetics
MH  - *Gene Expression Regulation, Viral/drug effects
MH  - HeLa Cells
MH  - Herpesvirus 4, Human/drug effects/*genetics
MH  - Humans
MH  - Hydroxyurea/pharmacology
MH  - In Situ Hybridization, Fluorescence
MH  - Nucleic Acid Synthesis Inhibitors/pharmacology
MH  - *Plasmids/drug effects
MH  - Polymerase Chain Reaction
MH  - RNA Interference
MH  - RNA, Small Interfering/metabolism
MH  - Stomach Neoplasms/pathology/*virology
MH  - Time Factors
MH  - Transfection
EDAT- 2009/05/28 09:00
MHDA- 2009/06/30 09:00
CRDT- 2009/05/28 09:00
PHST- 2009/02/10 00:00 [received]
PHST- 2009/03/27 00:00 [accepted]
PHST- 2009/03/17 00:00 [revised]
PHST- 2009/05/28 09:00 [entrez]
PHST- 2009/05/28 09:00 [pubmed]
PHST- 2009/06/30 09:00 [medline]
AID - 10.1007/s12272-009-1512-7 [doi]
PST - ppublish
SO  - Arch Pharm Res. 2009 May;32(5):729-36. doi: 10.1007/s12272-009-1512-7. Epub 2009 
      May 27.